TABLE 1

Patient characteristics

Age years; sexFollow-up yearsLung diseasePersonal and familial historyBiomarkersTreatments
Severe asthmaRecurrent hypoxaemia; FEV1/FVC %Chest CTOther eosinophilic organ involvementFamilial historyBEC ×109 cells·L−1; FENO ppb; % eosinophil BAL; total IgE IU·mL−1; specific IgE IU·mL−1ANCA and CRPOCS years; bolus of CS; impact on growth; normalised LFBiologics: follow-up years – TC, PC, NCBenralizumab follow-up months; possibility of OCS discontinuation; BEC×109 cells·L−1; FENO ppb
8;
girl
4Multiple hospitalisations /multiple intensive careYes; 84PIN; SAChronic rhinosinusitis; GORAtopic dermatitis1.810; 247; 0; 342; HDM 15.6Negative ANCA and CRP1; no; yesOmalizumab: 1 – NC5 –TC; yes;
0.58; NA
7;
boy
8Multiple hospitalisationsYes; 69PIN; HINasal polyposis; VKC; epilepsyFood allergies1.550; 150; NA; 66; positive SAENegative ANCA and CRP5; yes; yesOmalizumab: 1 – TC and relapse;
mepolizumab: 0.5 – TC and relapse
10 – TC; yes;
0; NA
5;
boy
4Multiple hospitalisationsYes; 71PIN; BWT; HI; ISTNasal polyposisAllergic rhinitis5.000; 35; 5; 92; positive SAENegative ANCA and CRP3; multiple; yes; yesOmalizumab: 1 – PC;
Mepolizumab: 1.5 – PC and relapse
12 – PC; yes;
0; NA
6;
boy
8Multiple hospitalisations /multiple intensive careYes; 71PIN; BWT; HI; DMAChronic rhinosinusitis
Chronic urticaria
None1.700; 120; 45; NA; negativeNegative ANCA and CRP3; multiples; yes; yesOmalizumab: 4 – TC and relapse;
mepolizumab: 0.5 – PC and relapse
6 – PC; no;
0; 111
9;
boy
4Multiple hospitalisationsNo; 68PIN; BWT; HIChronic rhinosinusitis
Atopic dermatitis
Asthma40.400; 49; 38; 1447; positive SAENegative ANCA and CRP1; multiples; no; yesOmalizumab: 0.5 – NC;
cyclosporine: 0.5 – PC;
mepolizumab: 0.5 – NC
10 – TC; yes;
0; NA
5;
girl
10Multiple hospitalisations /multiple intensive careYes; 57PIN; BWT; HI; IST; DMANasal polyposisType 1 diabetes2.100; 100; 7; 226; positive SAENegative ANCA and CRP4; yes; noOmalizumab: 4 – PC and relapse; mepolizumab: 0.5 – NC6 – TC; yes;
normalised LF
0; NA

FEV1: forced expiratory volume in 1; FVC: forced vital capacity; CT: computed tomography; FENO: exhaled nitric oxide fraction; CS: corticosteroid; PIN: pulmonary infiltrates and nodules; SA: segmental atelectasis; BWT: bronchial wall thickening; HI: hyperinflation; IST: interlobular septal thickening; DMA: diffuse mosaic attenuation; GOR: gastro-oesophageal reflux; VKC: vernal kerato-conjunctivitis; peak BEC: blood eosinophil count; BAL: bronchoalveolar lavage; peak total IgE (measured by ImmunoCAP): specific IgE towards common specific inhaled mould, food allergens and staphylococcal toxins (ImmunoCAP Phadiatop Infant; Uppsala, Sweden); HDM: house dust mites-specific IgE (≥0.35 kU·L−1); SAE: Staphylococcus aureus enterotoxins-specific IgE (≥0.35 kU·L−1); ANCA: anti-neutrophil cytoplasmic antibody; CRP: C-reactive protein; OCS: oral corticosteroid; LF: lung function; TC: total control; PC: partial control, as defined by the Global Initiative for Asthma; NC: no control; NA: not available.